Shanghai, China
The company is dedicated to the discovery, development, manufacturing, and commercialization of innovative therapeutics for hematologic malignancies and solid tumors. Antengene has a pipeline of 9 oncology programs at various stages, including clinical to commercial, with global rights for 6 programs and rights for the APAC region for 3 programs.
The company has obtained marketing authorizations for selinexor, its lead asset, in several Asia Pacific countries and regions, including China, South Korea, Singapore, and Australia.
The company's latest funding round was a $97.00M Series C investment on 20 July 2020. The investors in this round included GIC, Qiming Venture Partners, Boyu Capital, Fidelity, and Hillhouse Investment.
Antengene's commitment to developing groundbreaking therapeutics and its strategic expansion in the Asia Pacific region position it as a promising player in the global biopharmaceutical industry.
